行情

ZFGN

ZFGN

Zafgen
NASDAQ

实时行情|Nasdaq Last Sale

0.7694
+0.0404
+5.54%
已收盘, 16:00 10/22 EDT
开盘
0.7280
昨收
0.7290
最高
0.7700
最低
0.7203
成交量
28.76万
成交额
--
52周最高
11.70
52周最低
0.6300
市值
2,875.27万
市盈率(TTM)
-0.5197
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZFGN 新闻

  • 沪指弱势震荡 约翰逊月底“脱欧”计划落空
  • 新浪财经.1小时前
  • 英国议会力推延迟脱欧 首相约翰逊开始着眼大选
  • 新浪财经综合.2小时前
  • FAA局长:737 MAX复飞取得进展 但需数周时间进行审查
  • 新浪美股.2小时前
  • 米尔肯研究院发布中国最佳表现城市指数:成都居首
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+0.44%
制药与医学研究
+0.60%

热门股票

名称
价格
涨跌幅

ZFGN 简况

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
展开

Webull提供Zafgen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。